30
Participants
Start Date
March 31, 2021
Primary Completion Date
April 30, 2026
Study Completion Date
October 30, 2026
Kedrion IVIG 10%
Kedrion intravenous immunoglobulin (IVIg) 10%
NOT_YET_RECRUITING
Duke Children's Hospital & Health Center, Durham
NOT_YET_RECRUITING
Johns Hopkins All Children's Hospital, St. Petersburg
RECRUITING
Asthma and Allergy Center - Toledo, Toledo
RECRUITING
Louisiana State University Shreveport, Shreveport
RECRUITING
Vital Prospects Clinical Research Institute PC, Tulsa
RECRUITING
IMMUNOe Health and Research Centers, Centennial
RECRUITING
Velocity Clinical Research - MedPharmics - Lafayette, Chula Vista
RECRUITING
Benioff Children's Hospital - Mission Bay, San Francisco
COMPLETED
Dél-Pesti Centrumkórház - Országos Hematológiai És Infektológiai Intézet, Budapest
COMPLETED
SST Spedali Civili di Brescia, Brescia
COMPLETED
Azienda Ospedaliero-Universitaria - Ospedale Pediatrico Meyer, Florence
COMPLETED
I.R.C.C.S. Istituto Giannina Gaslini, Genova
COMPLETED
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinic, Milan
COMPLETED
Azienda Ospedaliera Universitaria "Federico II", Napoli
COMPLETED
Fondazione Policlinico Tor Vergata, Roma
COMPLETED
IRCCS Ospedale Pediatrico Bambino Gesù, Roma
COMPLETED
Centro Hospitalar Lisboa Central - Hospital Dona Estefânia, Lisbon
COMPLETED
Centro Hospitalar Universitário do Porto - Hospital Santo António, Porto
COMPLETED
Children's City Clinical Hospital No. 9 named after G.N. Speransky, Moscow City Health Department, Moscow
COMPLETED
Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology, Moscow
COMPLETED
Národný ústav detských chorôb (National Institute of Pediatric Diseases), Bratislava
Kedrion S.p.A.
INDUSTRY